Supplementary Figure 4: Effects of fluoxetine in Control mice for Figure 3.

All mice in this figure are homozygous fl1A (Control) littermates of the Nestin-Cre/fl1A mice shown in Figure 3. a) Timelines are for panels b-h. Control mice were pretreated with 200mg/kg tamoxifen or vehicle (three days, twice per day). Daily fluoxetine (18 mg/kg) or vehicle treatment began either when the mice were 8 weeks old (left, concurrent with the tamoxifen) or when they were 11 weeks old (right). Behavior commenced three weeks after initiation of fluoxetine treatment. For behavior, n = 15 mice per group. For neurogenesis, n = 8 mice per group that were randomly chosen from the behavioral cohort. b) NSF results. *** indicates significant effect of treatment and that p<.0001. Latencies were analyzed using Kaplan-Meier Survival Analysis with Bonferroni correction and Mantel-Cox p-values. c) Percentage weight loss and home cage consumption controls for the NSF experiment. The percentage of weight lost during the deprivation period and the amount of food consumed over 5 min when the mice were placed back into their home cage immediately after NSF exposure were calculated. No significant differences were seen among genotype and treatment groups (Two-Way ANOVA). d) EPM results. Bar graphs indicating open arm entries (left) and open arm duration (right) are shown. For both open arm entries (left) and open arm duration (right) there were only significant main effects of treatment (Two-Way ANOVA assessing pretreatment/treatment, *** indicates p<.0001 treatment effect for both open arm entries and open arm duration). e) FST results. For immobility duration there were only significant main effects of treatment (Two-Way ANOVA assessing pretreatment/treatment, *** indicates p<.0001 treatment effect). f) Proliferation results. For the number of BrdU-positive cells, there were only significant main effects of treatment (Two-Way ANOVA assessing pretreatment/treatment, *** indicates p<.0001 treatment effect). g) The number of abGCs. For the number of Dcx-positive cells, there were only significant main effects of treatment (Two-Way ANOVA assessing pretreatment/treatment, *** indicates p<.0001 treatment effect). h) The number of abGCs with tertiary dendrites. For the number of Dcx-positive cells with tertiary dendrites, there were only significant main effects of treatment (Two-Way ANOVA assessing pretreatment/treatment, *** indicates p<.0001 treatment effect). Bars and error bars throughout the figure represent mean ± SEM.